Lifecore Biomedical, Inc. (LFCR)
USD 5.03
(-5.01%)
USD 5.03
(-5.01%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 273.7 Million USD | 7.27% |
| 2023 | 255.15 Million USD | -13.64% |
| 2022 | 295.43 Million USD | -41.26% |
| 2021 | 502.92 Million USD | -7.09% |
| 2020 | 541.31 Million USD | 4.28% |
| 2019 | 519.09 Million USD | 28.26% |
| 2018 | 404.7 Million USD | 13.04% |
| 2017 | 358 Million USD | 4.23% |
| 2016 | 343.47 Million USD | -0.86% |
| 2015 | 346.46 Million USD | 10.47% |
| 2014 | 313.62 Million USD | 7.8% |
| 2013 | 290.94 Million USD | 4.77% |
| 2012 | 277.69 Million USD | 34.6% |
| 2011 | 206.31 Million USD | 3.05% |
| 2010 | 200.19 Million USD | 30.96% |
| 2009 | 152.86 Million USD | 1.51% |
| 2008 | 150.58 Million USD | 6.52% |
| 2007 | 141.36 Million USD | 18.77% |
| 2006 | 119.02 Million USD | 18.94% |
| 2005 | 100.07 Million USD | 7.6% |
| 2004 | 93 Million USD | -4.0% |
| 2003 | 96.88 Million USD | -10.13% |
| 2002 | 107.8 Million USD | -10.26% |
| 2001 | 120.12 Million USD | -9.85% |
| 2000 | 133.25 Million USD | 227.4% |
| 1999 | 40.7 Million USD | -4.01% |
| 1998 | 42.4 Million USD | -15.54% |
| 1997 | 50.2 Million USD | 30.73% |
| 1996 | 38.4 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 FY | 273.7 Million USD | 7.27% |
| 2024 Q2 | 245.81 Million USD | 0.08% |
| 2024 Q4 | 273.7 Million USD | 11.15% |
| 2024 Q3 | 246.24 Million USD | 0.17% |
| 2024 Q1 | 245.62 Million USD | -3.74% |
| 2023 Q4 | 255.15 Million USD | 8.04% |
| 2023 FY | 255.15 Million USD | -13.64% |
| 2023 Q1 | 269.09 Million USD | -6.69% |
| 2023 Q2 | 279.07 Million USD | 3.71% |
| 2023 Q3 | 236.15 Million USD | -15.38% |
| 2022 Q1 | 445.61 Million USD | -11.39% |
| 2022 Q3 | 325.58 Million USD | -22.87% |
| 2022 Q4 | 288.39 Million USD | -11.42% |
| 2022 Q2 | 422.12 Million USD | -5.27% |
| 2022 FY | 295.43 Million USD | -41.26% |
| 2021 Q3 | 509.82 Million USD | 2.14% |
| 2021 FY | 502.92 Million USD | -7.09% |
| 2021 Q1 | 506.18 Million USD | -6.49% |
| 2021 Q2 | 499.16 Million USD | -1.39% |
| 2021 Q4 | 502.92 Million USD | -1.35% |
| 2020 Q2 | 559.99 Million USD | 2.54% |
| 2020 FY | 541.31 Million USD | 4.28% |
| 2020 Q4 | 541.31 Million USD | -1.59% |
| 2020 Q3 | 550.06 Million USD | -1.77% |
| 2020 Q1 | 546.13 Million USD | 5.21% |
| 2019 FY | 519.09 Million USD | 28.26% |
| 2019 Q1 | 402.9 Million USD | -0.45% |
| 2019 Q2 | 411.65 Million USD | 2.17% |
| 2019 Q4 | 519.09 Million USD | 3.49% |
| 2019 Q3 | 501.58 Million USD | 21.85% |
| 2018 Q2 | 379.3 Million USD | 3.36% |
| 2018 Q1 | 366.96 Million USD | 2.5% |
| 2018 Q4 | 404.7 Million USD | 4.89% |
| 2018 FY | 404.7 Million USD | 13.04% |
| 2018 Q3 | 385.83 Million USD | 1.72% |
| 2017 Q2 | 341.34 Million USD | -0.71% |
| 2017 Q1 | 343.77 Million USD | 0.09% |
| 2017 Q4 | 358 Million USD | 3.43% |
| 2017 FY | 358 Million USD | 4.23% |
| 2017 Q3 | 346.13 Million USD | 1.4% |
| 2016 FY | 343.47 Million USD | -0.86% |
| 2016 Q2 | 361.1 Million USD | 5.41% |
| 2016 Q1 | 342.58 Million USD | -1.12% |
| 2016 Q3 | 328.67 Million USD | -8.98% |
| 2016 Q4 | 343.47 Million USD | 4.5% |
| 2015 Q1 | 325.93 Million USD | 3.93% |
| 2015 Q4 | 346.46 Million USD | 1.81% |
| 2015 Q2 | 341.09 Million USD | 4.65% |
| 2015 FY | 346.46 Million USD | 10.47% |
| 2015 Q3 | 340.3 Million USD | -0.23% |
| 2014 Q4 | 313.62 Million USD | 2.23% |
| 2014 Q3 | 306.78 Million USD | 1.5% |
| 2014 FY | 313.62 Million USD | 7.8% |
| 2014 Q2 | 302.25 Million USD | 3.93% |
| 2014 Q1 | 290.83 Million USD | -0.04% |
| 2013 Q3 | 282.99 Million USD | 1.76% |
| 2013 Q2 | 278.11 Million USD | 3.79% |
| 2013 Q1 | 267.96 Million USD | -3.5% |
| 2013 FY | 290.94 Million USD | 4.77% |
| 2013 Q4 | 290.94 Million USD | 2.81% |
| 2012 Q1 | 208.89 Million USD | 1.25% |
| 2012 Q3 | 211.54 Million USD | 1.02% |
| 2012 Q4 | 277.69 Million USD | 31.27% |
| 2012 FY | 277.69 Million USD | 34.6% |
| 2012 Q2 | 209.4 Million USD | 0.25% |
| 2011 Q2 | 207.02 Million USD | 0.63% |
| 2011 Q3 | 208.67 Million USD | 0.8% |
| 2011 FY | 206.31 Million USD | 3.05% |
| 2011 Q4 | 206.31 Million USD | -1.13% |
| 2011 Q1 | 205.72 Million USD | 2.76% |
| 2010 Q3 | 159.57 Million USD | -0.51% |
| 2010 Q1 | 163.66 Million USD | 6.62% |
| 2010 FY | 200.19 Million USD | 30.96% |
| 2010 Q2 | 160.39 Million USD | -2.0% |
| 2010 Q4 | 200.19 Million USD | 25.46% |
| 2009 Q3 | 148.22 Million USD | -1.79% |
| 2009 Q2 | 150.92 Million USD | -1.22% |
| 2009 Q4 | 153.49 Million USD | 3.56% |
| 2009 FY | 152.86 Million USD | 1.51% |
| 2009 Q1 | 152.78 Million USD | 1.46% |
| 2008 FY | 150.58 Million USD | 6.52% |
| 2008 Q1 | 127.06 Million USD | -10.12% |
| 2008 Q2 | 127.97 Million USD | 0.72% |
| 2008 Q4 | 150.58 Million USD | 13.02% |
| 2008 Q3 | 133.23 Million USD | 4.11% |
| 2007 Q4 | 141.36 Million USD | 4.18% |
| 2007 Q2 | 125.91 Million USD | 10.18% |
| 2007 FY | 141.36 Million USD | 18.77% |
| 2007 Q3 | 135.69 Million USD | 7.76% |
| 2007 Q1 | 114.28 Million USD | -3.99% |
| 2006 Q3 | 119.02 Million USD | 8.26% |
| 2006 Q2 | 109.94 Million USD | 11.1% |
| 2006 FY | 119.02 Million USD | 18.94% |
| 2006 Q4 | 119.02 Million USD | 0.0% |
| 2006 Q1 | 98.95 Million USD | -1.12% |
| 2005 Q1 | 93.6 Million USD | 0.64% |
| 2005 FY | 100.07 Million USD | 7.6% |
| 2005 Q4 | 100.07 Million USD | -0.95% |
| 2005 Q3 | 101.03 Million USD | 1.53% |
| 2005 Q2 | 99.5 Million USD | 6.31% |
| 2004 Q1 | 90.96 Million USD | -6.39% |
| 2004 FY | 93 Million USD | -4.0% |
| 2004 Q3 | 95.95 Million USD | -0.23% |
| 2004 Q2 | 96.17 Million USD | 5.73% |
| 2004 Q4 | 93 Million USD | -3.07% |
| 2003 Q4 | 97.17 Million USD | -6.25% |
| 2003 FY | 96.88 Million USD | -10.13% |
| 2003 Q3 | 103.65 Million USD | -3.85% |
| 2003 Q2 | 107.8 Million USD | -4.05% |
| 2003 Q1 | 112.35 Million USD | -3.19% |
| 2002 FY | 107.8 Million USD | -10.26% |
| 2002 Q2 | 120.12 Million USD | -4.42% |
| 2002 Q3 | 122.63 Million USD | 2.09% |
| 2002 Q1 | 125.68 Million USD | -0.43% |
| 2002 Q4 | 116.06 Million USD | -5.36% |
| 2001 Q1 | 131.14 Million USD | 5.99% |
| 2001 FY | 120.12 Million USD | -9.85% |
| 2001 Q4 | 126.22 Million USD | -2.62% |
| 2001 Q2 | 133.25 Million USD | 1.61% |
| 2001 Q3 | 129.62 Million USD | -2.72% |
| 2000 Q1 | 40.4 Million USD | -5.39% |
| 2000 FY | 133.25 Million USD | 227.4% |
| 2000 Q3 | 120.3 Million USD | 195.58% |
| 2000 Q2 | 40.7 Million USD | 0.74% |
| 2000 Q4 | 123.73 Million USD | 2.85% |
| 1999 Q3 | 46 Million USD | 8.49% |
| 1999 Q4 | 42.7 Million USD | -7.17% |
| 1999 Q1 | 38.5 Million USD | -4.94% |
| 1999 Q2 | 42.4 Million USD | 10.13% |
| 1999 FY | 40.7 Million USD | -4.01% |
| 1998 Q2 | 50.2 Million USD | 13.83% |
| 1998 Q4 | 40.5 Million USD | -9.4% |
| 1998 Q3 | 44.7 Million USD | -10.96% |
| 1998 FY | 42.4 Million USD | -15.54% |
| 1998 Q1 | 44.1 Million USD | -3.71% |
| 1997 Q3 | 37 Million USD | -3.65% |
| 1997 Q1 | 39.7 Million USD | -3.41% |
| 1997 Q2 | 38.4 Million USD | -3.27% |
| 1997 Q4 | 45.8 Million USD | 23.78% |
| 1997 FY | 50.2 Million USD | 30.73% |
| 1996 Q4 | 41.1 Million USD | 0.0% |
| 1996 FY | 38.4 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Cosmos Health Inc. | 66.29 Million USD | -312.851% |
| Safety Shot Inc | 12.7 Million USD | -2053.577% |
| Bright Green Corporation | 17.4 Million USD | -1472.725% |
| Embecta Corp. | 1.21 Billion USD | 77.462% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 69.737% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -376.683% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 76.061% |
| Dynavax Technologies Corporation | 997.09 Million USD | 72.55% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -32.997% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 62.419% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 82.615% |
| PainReform Ltd. | 9.93 Million USD | -2656.314% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -900.85% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -900.85% |
| SCYNEXIS, Inc. | 128.41 Million USD | -113.144% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -1083.471% |
| Journey Medical Corporation | 76.84 Million USD | -256.156% |
| Alpha Teknova, Inc. | 128.58 Million USD | -112.854% |
| Procaps Group, S.A. | 460.18 Million USD | 40.524% |
| Theratechnologies Inc. | 77.76 Million USD | -251.942% |
| Harrow Health, Inc. | 311.75 Million USD | 12.206% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -1737.79% |
| Biofrontera Inc. | 27.93 Million USD | -879.887% |
| DURECT Corporation | 45.18 Million USD | -505.683% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 80.574% |
| Cronos Group Inc. | 1.13 Billion USD | 75.869% |
| OptiNose, Inc. | 107.72 Million USD | -154.065% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 41.898% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -389.199% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -1087.575% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 40.503% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -2196.509% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -234.697% |
| Radius Health, Inc. | 1.71 Billion USD | 84.05% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -413.637% |
| ProPhase Labs, Inc. | 91.92 Million USD | -197.738% |
| Phibro Animal Health Corporation | 982.18 Million USD | 72.133% |
| Procaps Group S.A. | 460.18 Million USD | 40.524% |
| Alvotech | 950.09 Million USD | 71.192% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -531.975% |
| Viatris Inc. | 47.68 Billion USD | 99.426% |
| Rockwell Medical, Inc. | 52.17 Million USD | -424.605% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -131.764% |
| SIGA Technologies, Inc. | 254.83 Million USD | -7.403% |
| Tilray Brands, Inc. | 4.33 Billion USD | 93.687% |
| Shineco, Inc. | 84.17 Million USD | -225.141% |
| PetIQ, Inc. | 868.22 Million USD | 68.476% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -3143.602% |
| Incannex Healthcare Limited | 17.04 Million USD | -1505.573% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 91.582% |
| Alimera Sciences, Inc. | 153.52 Million USD | -78.28% |
| Silver Spike Investment Corp. | 88.57 Million USD | -209.001% |
| Assertio Holdings, Inc. | 286.41 Million USD | 4.44% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -4498.692% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -709.87% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -776.043% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -1966.059% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -4.816% |
| Hempacco Co., Inc. | 18.04 Million USD | -1416.936% |
| Talphera, Inc. | 20.39 Million USD | -1242.005% |
| Alvotech | 950.09 Million USD | 71.192% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 32.612% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 83.424% |
| Currenc Group, Inc. | 141.49 Million USD | -93.442% |
| Kamada Ltd. | 351.96 Million USD | 22.237% |
| Indivior PLC | 1.95 Billion USD | 85.973% |
| Evoke Pharma, Inc. | 7.06 Million USD | -3772.112% |
| Flora Growth Corp. | 23.62 Million USD | -1058.478% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -1966.059% |
| Evolus, Inc. | 188.99 Million USD | -44.817% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 78.613% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 81.909% |
| Akanda Corp. | 8.83 Million USD | -2996.179% |